10 Firms Heavily Hit by Market Pessimism

1. Sarepta Therapeutics Inc. (NASDAQ:SRPT)

Sarepta fell heavily by 27.44 percent on Tuesday to finish at $73.54 apiece as investors disposed of shares in the company following twin news of death associated with its treatment Elevidys.

On Tuesday, SRPT announced that a young patient succumbed to acute liver failure after receiving the Sarepta Elevidys therapy, the only FDA-approved gene therapy for Duchenne muscular dystrophy.

While the risk has already been flagged on the Elevidys label, acute liver injuries leading to death have not been previously reported in clinical testing or real-world use of Elevidys.

SRPT said that the patient had a recent cytomegalovirus (CMV) infection which allegedly contributed to the death. The infection can damage the liver, leading to CMV hepatitis, which is fatal to those with weak immune systems.

While we acknowledge the potential of SRPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as SRPT but trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.